Anika Therapeutics | ANIK - Операционный доход





Операционный доход Изменить Дата
Abbott USD 1.85B 399M 2026-03
Agenus USD 14.4M 19.26M 2025-12
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD 40.81M 3.3M 2025-12
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Integra LifeSciences USD 66M 54.24M 2025-12
Intrexon USD -60.84M 26.62M 2024-06
J&J USD 6.62B 1.03B 2026-03
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
Ligand Pharmaceuticals USD 158.89M 149.17M 2025-09
MacroGenics USD -12.1M 30.74M 2025-12
Merit Medical Systems USD 44.16M 10.04M 2026-03
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 1.94B 239M 2026-03
Smith & Nephew USD 440M 50M 2025-12
Stryker USD 1.1B 867M 2026-03
Surmodics USD 58K 5.7M 2025-06
Veracyte USD 24.63M 1.52M 2025-12
Xencor USD -53.63M 6.11M 2025-12
Zimmer Biomet Holdings USD 395.1M 92.2M 2026-03